ザ・ベーシックメソッド　心不全　非薬物治療

出版社： メジカルビュー社
著者：
発行日： 2022-10-10
分野： 臨床医学：内科  >  循環器一般
ISBN： 9784758319799
電子書籍版： 2022-10-10 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

6,600 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

6,600 円(税込)

購入する

商品紹介

最新の心不全ガイドラインで薬物治療と併せて治療の大きな柱の1つとして位置付けられた非薬物治療（植込み型除細動器，心臓再同期療法，SHDインターベンション治療 ，補助人工心臓・心臓移植，等）の手技と管理を豊富な図版・イラストによりビジュアルに解説。基礎知識と実践をリンクさせることで臨床のさまざまな場面で役立つ構成となっている。
姉妹編『ザ・ベーシックメソッド 心不全 薬物治療』と併せて，心不全患者の治療・管理を包括的・体系的に学べる実践的入門書！

目次

  • I章　心不全　非薬物治療のオキテーまずはこれだけ
    　1　急性期の非薬物治療
    　2　慢性期の非薬物治療

    II章　急性期の非薬物治療
    　1　人工呼吸管理―NPPV，気管挿管による人工呼吸，VV-ECMO
    　2　血液浄化療法
    　3　IABP，PCPS/VA-ECMO　
    　4　Impella®
    　5　体外設置型補助人工心臓（VAD）

    III章　慢性期の非薬物治療
    　1　植込み型除細動器（ICD，S-ICD）
    　2　着用型自動除細動器（WCD）
    　3　心臓再同期療法（CRT，CRT-D）　―適応，手法や管理，合併症，遠隔モニタリング
    　4　心房細動カテーテルアブレーション　
    　5　経カテーテル的大動脈弁留置術（TAVI）
    　6　MitraClip™
    　7　植込型補助人工心臓（VAD）
    　8　心臓移植

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I章 心不全 非薬物治療のオキテ - まずはこれだけ

P.9 掲載の参考文献
1) 日本循環器学会/日本心不全学会合同ガイドライン:急性・慢性心不全診療ガイドライン(2017年改訂版). 2021更新. https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf
 
2) Green SM, Martinez-Rumayor A, Gregory SA, et al:Clinical uncertainty, diagnostic accuracy, and outcomes in emergency department patients presenting with dyspnea. Arch Intern Med 168:741-748, 2008.
PubMed
3) Bozkurt B, Coats AJ, Tsutsui H, et al:Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. J Card Fail:S1071-9164 (21) 00050-6, 2021. Online ahead of print.
 
4) Maisel AS, Nakao K, Ponikowski P, et al:Japanese-Western consensus meeting on biomarkers. Int Heart J 52:253-265, 2011.
PubMed
5) 日本心不全学会:血中BNPやNT-proBNP値を用いた心不全診療の留意点について. http://www.asas.or.jp/jhfs/topics/bnp201300403.html
 
6) Lam CSP, Li Y-H, Bayes-Genis A, et al:The role of N-terminal pro-B-type natriuretic peptide in prognostic evaluation of heart failure. J Chin Med Assoc 82:447-451, 2019.
 
7) Enghard P, Rademacher S, Nee J, et al:Simplified lung ultrasound protocol shows excellent prediction of extravascular lung water in ventilated intensive care patients. Crit Care 1:36, 2015.
PubMed
8) Freund Y, Cachanado M, Delannoy Q, et al:Effect of an Emergency Department Care Bundle on 30-Day Hospital Discharge and Survival Among Elderly Patients With Acute Heart Failure:The ELISABETH Randomized Clinical Trial. JAMA 324: 1948-1956, 2020.
PubMed
9) Baran DA, Grines CL, Bailey S, et al:SCAI clinical expert consensus statement on the classification of cardiogenic shock: This document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019. Catheter Cardiovasc Interv 94:29-37, 2019.
 
10) Jentzer JC, van Diepen S, Barsness GW, et al:Cardiogenic Shock Classification to Predict Mortality in the Cardiac Intensive Care Unit. J Am Coll Cardiol 74:2117-2128, 2019.
PubMed
11) Masip J:Noninvasive Ventilation in Acute Heart Failure. Curr Heart Fail Rep 16:89-97, 2019.
PubMed
12) Sato N, Kajimoto K, Keida T, et al:TEND Investigators. Clinical features and outcome in hospitalized heart failure in Japan (from the ATTEND Registry). Circ J 77:944-945, 2013.
PubMed
13) Srivastava M, Harrison N, Caetano AFS, et al:Ultrafiltration for acute heart failure. Cochrane Database Syst Rev 1:CD013593, 2022.
PubMed
14) Costanzo MR, Guglin ME, Saltzberg MT, et al:UNLOAD Trial Investigators. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 49:675-683, 2007.
PubMed
15) Bart BA, Goldsmith SR, Lee KL, et al:Heart Failure Clinical Research Network. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 367:2296-2304, 2012.
PubMed
P.18 掲載の参考文献
1) 日本循環器学会/日本心不全学会合同ガイドライン:2021年JCS/JHFSガイドラインフォーカスアップデート版 急性・慢性心不全診療. 2021. https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Tsutsui.pdf
 
2) 日本循環器学会/日本心臓リハビリテーション学会合同ガイドライン:心血管疾患におけるリハビリテーションに関するガイドライン(2021年改訂版). 2021 . https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Makita.pdf
 
3) 日本循環器学会/日本心不全学会合同ガイドライン:急性・慢性心不全診療ガイドライン(2017年改訂版). 2021更新. https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf
 

II章 急性期の非薬物治療

P.25 掲載の参考文献
1) Adams KF, Jr. , Fonarow GC, Emerman CL, et al:Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149:209-216, 2005.
 
2) Bradley TD, Holloway RM, McLaughlin PR, et al:Cardiac output response to continuous positive airway pressure in congestive heart failure. Am Rev Respir Dis 145:377-382, 1992.
PubMed
3) Mebazaa A, Gheorghiade M, Pina IL, et al:Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. Crit Care Med 36:S129-139, 2008.
PubMed
4) Nohria A, Tsang SW, Fang JC, et al:Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol 41:1797-1804, 2003.
PubMed
P.37 掲載の参考文献
1) Ronco C, Happio M, House AA, et al:Cardiorenal syndrome. J Am Coll Cardiol 52:1527-1539, 2008.
 
2) Ronco C, McCullough P, Anker SD, et al:Cardio-renal syndromes:report from the consensus conference of the Acute Dialysis Quality Initiative. Eur Heart J 31:703-711, 2010.
PubMed
3) Mullens W, Abrahams Z, Francis GS, et al:Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 53:589-596, 2009.
PubMed
4) 日本循環器学会/日本心不全学会合同ガイドライン:急性・慢性心不全診療ガイドライン(2017年改訂版). 2021更新. https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf
 
5) Constanzo MR, Guglin ME, Saltzberg MT, et al:UNLOAD Trial Investigators: Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 49:675-683, 2007.
 
6) Bart BA, Goldsmith SR, Lee KL, et al:Heart Failure Clinical Research Network: Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 367:2296-2304, 2012.
PubMed
7) Marenzi G, Muratori M, Cosentino ER, et al:Continuous ultrafiltration for congestive heart failure. The CUORE Trial. J Card Fail 20:9-17, 2014.
 
8) Costanzo MR, Negoianu D, Jaski BE, et al:Aquapheresis Versus Intravenous Diuretics and Hospitalizations for Heart Failure. JACC Heart Fail 4:95-105, 2016.
PubMed
9) Wobbe B, Wagner J, Szabo DK, et al:Ultrafiltration is better than diuretic therapy for volume-overloaded acute heart failure patients: a meta-analysis. Heart Fail Rev 26:577-585, 2021.
PubMed
10) Wang JM, Zheng YM, Jin HX:Ultrafiltration for patients with acute decompensated heart failure: A systematic review and meta-analysis. Medicine (Baltimore) 100(50):e28029, 2021.
 
11) Constanzo MR, Saltzberg M, O'Sullivan J, et al:Early ultrafiltration in patients with decompensated heart failure and diuretic resistance. J Am Coll Cardiol 46:2047-2051, 2005.
 
12) Uchino S, Bellomo R, Morimatsu H, et al:Discontinuation of continuous renal replacement therapy:A post hoc analysis of a prospective multicenter observational study. Crit Care Med 37:2576-2582, 2009.
PubMed
P.43 掲載の参考文献
1) Iida N, Seo Y, Sai S, et al:Clinical Implications of Intrarenal Hemodynamic Evaluation by Doppler Ultrasonography in Heart Failure. JACC Heart Fail 4:674-682, 2016.
PubMed
2) Mullens W, Abrahams Z, Skouri HN, et al:Elevated intra-abdominal pressure in acute decompensated heart failure:a potential contributor to worsening renal function ? J Am Coll Cardiol 51:300-306, 2008.
PubMed
P.49 掲載の参考文献
1) 日本循環器学会/日本心不全学会合同ガイドライン:急性・慢性心不全診療ガイドライン(2017年改訂版). 2022更新. https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf
 
2) Stevenson LW, Pagani FD, Young JB, et al:INTERMACS profiles of advanced heart failure:the current picture. J Heart Lung Transplant 28:535-541, 2009.
PubMed
3) Atkinson TM, Ohman EM, O'Neill WW, et al:A Practical Approach to Mechanical Circulatory Support in Patients Undergoing Percutaneous Coronary Intervention. An Interventional Perspective. J Am Coll Cardiol Intv 9:871-883, 2016.
 
4) Nishimura M, Nishimura T, Ishikawa M, et al:Importance of luxury flow for critically ill patients receiving a left ventricular assist system. J Artif Organs 9:209-213, 2006.
PubMed
5) 赤嶺 斉, 新見能成:ECMOの生理学. INTENSIVIST 5:269-278, 2013
 
6) Rao P, Khalpey Z, Smith R, et al:Venoarterial extracorporeal membrane oxygenation for cardiogenic shock and cardiac arrest. Circ Heart Fail 11:e004905, 2018
PubMed
P.54 掲載の参考文献
1) Shah A, Dave S, Goerlich CE, Kaczorowski DJ:Hybrid and parallel extracorporeal membrane oxygenation circuits. JTCVS Tech 8:77-85, 2021.
PubMed
2) Napp LC, Kuhn C, Hoeper MM, et al:Cannulation strategies for percutaneous extracorporeal membrane oxygenation in adults. Clin Res Cardiol 105:283-296, 2016.
PubMed
P.63 掲載の参考文献
1) Thiele H, Ohman EM, Desch S, et al:Management of cardiogenic shock, Eur Heart J 35:1223-1230, 2015.
 
2) Basir MB, Schreiber TL, Grines CL, et al:Effect of Early Initiation of Mechanical Circulatory Support on Survival in Cardiogenic Shock. Am J Cardiol 119(6):845-851, 2017.
PubMed
3) Atkinson TM, Ohman EM, O'Neill WW, et al:Interventional Scientific Council of the American College of Cardiology. A Practical Approach to Mechanical Circulatory Support in Patients Undergoing Percutaneous Coronary Intervention:An Interventional Perspective. JACC Cardiovasc Interv 9:871-883, 2016.
 
4) 日本循環器学会/日本心不全学会合同ガイドライン:2021年JCS/JHFSガイドライン フォーカスアップデート版 急性・慢性心不全診療. 2021. https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Tsutsui.pdf
 
5) 補助人工心臓治療関連学会協議会HP:循環補助用心内留置型ポンプカテーテルの適正使用指針. https://j-pvad.jp/
 
6) Jentzer JC, van Diepen S, Barsness GW, et al:Cardiogenic Shock Classification to Predict Mortality in the Cardiac Intensive Care Unit. J Am Coll Cardiol 74(17):2117-2128, 2019.
PubMed
7) Schrage B, Burkhoff D, Rubsamen N, et al:Unloading of the Left Ventricular During Venoarterial Extracorporeal Membrane Oxygenation Therapy in Cardiogenic Shock. J Am Coll Cardiol HF 6:1035-1043, 2018.
 
8) 肥後太基:重症心不全治療におけるECMOの役割. 循環制御 42:73-74, 2021.
 
9) Flierl U, Tongers J, Berliner D, et al:Acquired von Willebrand Syndrome in Cardiogenic Shock Patients on Mechanical Circulatory Microaxial Pump Support. PLoS One 12(8): e0183193, 2017.
 
10) Anderson MB, Goldstein J, Milano C, et al:Benefits of a novel percutaneous ventricular assist device for right heart failure:The prospective RECOVER RIGHT study of the Impella RP device. J Heart Lung Transplant 34:1549-1560, 2015.
 
11) Saxena A, Garan R, Kapur N, et al:Value of Hemodynamic Monitoring in Patients with Cardiogenic Shock Undergoing Mechanical Circulatory Support. Circulation 141:1184-1197, 2020.
 
12) Nakamura M, Imamura T, Ueno H, et al:Current Indication and Practical Management of Percutaneous left Ventricular Assist Device Support Therapy in Japan. J Cardiol 75:228-232, 2020.
PubMed
P.75 掲載の参考文献
1) Webb JG, Sleeper LA, Buller CE, et al:Implications of the timing of onset of cardiogenic shock after acute myocardial infarction:a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shock? J Am Coll Cardiol 36:1084-1090, 2000.
PubMed
2) O'Neill WW, Schreiber T, Wohns DH, et al:The current use of Impella 2.5 in acute myocardial infarction complicated by cardiogenic shock:results from the USpella Registry. J Interv Cardiol 27:1-11, 2014.
PubMed
3) Basir MB, Schreiber TL, Grines CL, et al:Effect of Early Initiation of Mechanical Circulatory Support on Survival in Cardiogenic Shock. Am J Cardiol 119:845-851, 2017.
PubMed
4) Napp LC, Kuhn C, Hoeper MM, et al:Cannulation strategies for percutaneous extracorporeal membrane oxygenation in adults. Clin Res Cardiol 105:283-296, 2016.
PubMed
P.83 掲載の参考文献
1) 日本循環器学会/日本心不全学会合同ガイドライン:急性・慢性心不全診療ガイドライン(2017年改訂版). 2022更新. https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf
 
2) Nitta D, Kinugawa K, Imamura T, et al:A Useful Scoring System for Predicting Right Ventricular Assist Device Requirement Among Patients with a Paracorporeal Left Ventricular Assist Device. Int Heart J 59:983-990, 2018.
PubMed
3) Wever-Pinzon O, Drakos SG, McKellar SH, et al:Cardiac recovery during long-term left ventricular assist device support. J Am Coll Cardiol 68:1540-1553, 2016.
PubMed
4) Imamura T, Kinugawa K, Nitta D, et al:Novel scoring system using postoperative cardiopulmonary exercise testing predicts future explantation of left ventricular assist device. Circ J 79:560-566, 2015.
PubMed
P.90 掲載の参考文献
1) Adachi Y, Kinoshita O, Hatano M, et al:Successful bridge to recovery in fulminant myocarditis using a biventricular assist device: a case report. J Med Case Rep 11:295, 2017.
PubMed
2) Imamura T, Kinugawa K, Nitta D, et al:Opening of native aortic valve accomplished after left ventricular assist device implantation in patients with insufficient preoperative beta-blocker treatment. Int Heart J 56:303-308, 2015.
PubMed

III章 慢性期の非薬物治療

P.101 掲載の参考文献
1) 日本循環器学会/日本不整脈心電学会合同ガイドライン:不整脈非薬物治療ガイドライン(2018年改訂版). 2021更新. https://www.j-circ.or.jp/cms/wp-content/uploads/2018/07/JCS2018_kurita_nogami.pdf
 
2) Connolly SJ, Hallstrom AP, Cappato R, et al:Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J 21:2071-2078, 2000.
PubMed
3) Noda T, Kurita T, Nitta T, et al:Significant impact of electrical storm on mortality in patients with structural heart disease and an implantable cardiac defibrillator. Int J Cardiol 255:85-91, 2018.
 
4) Matsue Y, Suzuki M, Nishizaki M, et al:Clinical implications of an implantable cardioverter-defibrillator in patients with vasospastic angina and lethal ventricular arrhythmia. J Am Coll Cardiol 60:908-913, 2012.
PubMed
5) Greenberg H, Case RB, Moss AJ, et al:Analysis of mortality events in the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II). J Am Coll Cardiol 43:1459-1465, 2004.
 
6) Tanno K, Miyoshi F, Watanabe N, et al:MADIT II. The Multicenter Automtic Defibrillator Implantation Trial. Are the MADIT II criteria for ICD implantation appropriate for Japanese patients? Circ J 69:19-22, 2005.
 
7) Satake H, Fukuda K, Sakata Y, et al:Current status of primary prevention of sudden cardiac death with implantable cardioverter defibrillator in patients with chronic heart failure--a report from the CHART-2 Study. Circ J 79:381-390, 2015.
PubMed
8) Kadish A, Dyer A, Daubert JP, et al:Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 350:2151-2158, 2004.
PubMed
9) Kober L, Thune JJ, Nielsen JC, et al:Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. N Engl J Med 375:1221-1230, 2016.
PubMed
10) Bardy GH, Lee KL, Mark DB, et al:Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352:225-237, 2005.
 
11) Stiles MK, Fauchier L, Morillo CA, Wilkoff BL:2019 HRS/EHRA/APHRS/LAHRS focused update to 2015 expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Heart Rhythm 17:e220-e228, 2020.
PubMed
12) Daubert JP, Zareba W, Cannom DS, et al:Inappropriate implantable cardioverter-defibrillator shocks in MADITII:frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol 51:1357-1365, 2008.
 
13) Poole JE, Johnson GW, Hellkamp AS, et al:Prognostic Importance of Defibrillator Shocks in Patients with Heart Failure. N Engl J Med 359:1009-1017, 2008.
PubMed
14) Moss AJ, Schuger C, Beck CA, et al:Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med 367:2275-2283, 2012.
PubMed
15) Crossley GH, Boyle A, Vitense H, et al:The CONNECT (Clinical Evaluation of Remote Notification to Reduce Time to Clinical Decision) trial:the value of wireless remote monitoring with automatic clinician alerts. J Am Coll Cardiol 57:1181-1189, 2011.
PubMed
P.123 掲載の参考文献
1) Solomon SD, Zelenkofske S, McMurray JJ, et al:Valsartan in Acute Myocardial Infarction Trial I:Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 352:2581-2588, 2005.
 
2) Epstein AE, Abraham WT, Bianco NR, et al:Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post-myocardial infarction. J Am Coll Cardiol 62:2000-2007, 2013.
PubMed
3) Hohnloser SH, Kuck KH, Dorian P, et al:Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 351:2481-2488, 2004.
PubMed
4) Steinbeck G, Andresen D, Seidl K, et al:Defibrillator implantation early after myocardial infarction. N Engl J Med 361:1427-1436, 2009.
PubMed
5) Brooks GC, Lee BK, Rao R, et al:Predicting Persistent Left Ventricular Dysfunction Following Myocardial Infarction:The PREDICTS Study. J Am Coll Cardiol. 67:1186-1196, 2016.
PubMed
6) Vaughan-Sarrazin MS, Hannan EL, Gormley CJ, Rosenthal GE:Mortality in Medicare beneficiaries following coronary artery bypass graft surgery in states with and without certificate of need regulation. JAMA 288:1859-1866, 2002.
PubMed
7) Toda K, Mackenzie K, Mehra MR, et al:Revascularization in severe ventricular dysfunction(15% < OR = LVEF < OR = 30%): a comparison of bypass grafting and percutaneous intervention. Ann Thorac Surg 74:2082-2087(discussion 2087), 2002.
 
8) Duncker D, Haghikia A, Konig T, et al:Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular function-value of the wearable cardioverter/defibrillator. Eur J Heart Fail 16:1331-1336, 2014.
PubMed
9) Tsuchihashi K, Ueshima K, Uchida T, et al:Transient left ventricular apical ballooning without coronary artery stenosis:a novel heart syndrome mimicking acute myocardial infarction. J Am Coll Cardiol 38:11-18, 2001.
PubMed
10) McNamara DM, Starling RC, Cooper LT, et al:Clinical and demographic predictors of outcomes in recent onset dilated cardiomyopathy:results of the IMAC (Intervention in Myocarditis and Acute Cardiomyopathy) -2 study. J Am Coll Cardiol 58:112-1118, 2011.
 
11) Singh M, Wang NC, Jain Sz, et al:Utility of the Wearable Cardioverter-Defibrillator in Patients With Newly Diagnosed Cardiomyopathy:A Decade-Long Single-Center Experience. J Am Coll Cardiol 66:2607-2613, 2015.
 
12) Chung MK, Szymkiewicz SJ, Shao M, et al:Aggregate national experience with the wearable cardioverter-defibrillator:event rates, compliance, and survival. J Am Coll Cardiol 56:194-203, 2010.
PubMed
13) Olgin JE, Pletcher MJ, Vittinghoff E, et al:Wearable Cardioverter-Defibrillator after Myocardial Infarction. N Engl J Med 379:1205-1215, 2018.
PubMed
14) Kutyifa V, Moss AJ, Klein H, et al:Use of the wearable cardioverter defibrillator in high-risk cardiac patients:data from the Prospective Registry of Patients Using the Wearable Cardioverter Defibrillator (WEARIT-II Registry). Circulation 132:1613-1619, 2015.
 
15) Zishiri ET, Williams S, Cronin EM, et al:Early risk of mortality after coronary artery revascularization in patients with left ventricular dysfunction and potential role of the wearable cardioverter defibrillator. Circ Arrhythm Electrophysiol 6:117-128, 2013.
PubMed
16) Wassnig NK, Gunther M, Quick S, et al:Experience With the Wearable Cardioverter-Defibrillator in Patients at High Risk for Sudden Cardiac Death. Circulation 134:635-643, 2016.
PubMed
17) Klein HU, Meltendorf ULF, Reek S, et al:Bridging a Temporary High Risk of Sudden Arrhythmic Death. Experience with the Wearable Cardioverter Defibrillator(WCD). Pacing and Clinical Electrophysiology 33:353-367, 2010.
PubMed
P.132 掲載の参考文献
1) Sasaki S, Tomita H, Shibutani S, et al:Usefulness of the wearable cardioverter-defibrillator in patients at high risk for sudden cardiac death. Circ J 78:2987-2989, 2014.
PubMed
P.144 掲載の参考文献
1) Abraham WT, Fisher WG, Smith AL, et al:Cardiac resynchronization in chronic heart failure. N Engl J Med J 46:1845-1853, 2002.
PubMed
2) Cleland JG, Daubert JC, Erdmann E, et al:The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352:1539-1549, 2005.
PubMed
3) Linde C, Abraham WT, Gold MR, et al:Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol 52:1834-1843, 2008.
PubMed
4) Tang AS, Wells GA, Talajic M, et al:Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 363:2385-2395, 2010.
PubMed
5) Yu CM, Lin H, Zhang Q, Sanderson JE:High prevalence of left ventricular systolic and diastolic asynchrony in patients with congestive heart failure and normal QRS duration. Heart Jan 89:54-60, 2003.
PubMed
6) Yu CM, Chan YS, Zhang Q, et al:Benefits of cardiac resynchronization therapy for heart failure patients with narrow QRS complexes and coexisting systolic asynchrony by echocardiography. J Am Coll Cardiol 48:2251-2257, 2006.
PubMed
7) Chung ES, Leon AR, Tavazzi L, et al:Results of the Predictors of Response to CRT (PROSPECT) trial. Circulation 117:2608-2616, 2008.
PubMed
8) Mullens W, Verga T, Grimm RA, et al:Persistent hemodynamic benefits of cardiac resynchronization therapy with disease progression in advanced heart failure. J Am Coll Cardiol 53:600-607, 2009.
PubMed
9) Pappone C, Calovic Z, Vicedomini G, et al:Improving cardiac resynchronization therapy response with multipoint left ventricular pacing: Twelve-month follow-up study. Heart Rhythm 12:1250-1258, 2015.
PubMed
10) Birnie D, Lemke B, Aonuma K, et al:Clinical outcomes with synchronized left ventricular pacing:analysis of the adaptive CRT trial. Heart Rhythm 10:1368-1374, 2013.
PubMed
11) Virani SA, Sharma V, McCann M, et al:Prospective evaluation of integrated device diagnostics for heart failure management: results of the TRIAGE-HF study. ESC Heart Fail 5 (5):809-817, 2018.
PubMed
12) Boehmer JP, Hariharan R, Devecchi FG, et al:A Multisensor Algorithm Predicts Heart Failure Events in Patients With Implanted Devices. JACC Heart Fail 5 (3):216-225, 2017.
PubMed
13) Hindricks G, Taborsky M, Glikson M, et al:Implant-based multiparameter telemonitoring of patients with heart failure (IN-TIME):a randomised controlled trial. Lancet 384:583-590, 2014.
 
14) Miyoshi A, Nishii N, Okamoto Y, et al:Lifestyle Modification or Medication to Improve Condition of Patients With Asymptomatic Heart Failure - Monitoring and Management of OptiVol Alert to Reduce Heart Failure Hospitalization II (MOMOTAROII) Study. Circ J 84 (3):456-462, 2020.
PubMed
P.156 掲載の参考文献
1) Zecchin M, Proclemer A, Magnani S, et al:Long-term outcome of 'super-responder' patients to cardiac resynchronization therapy. Europace 16:363-371, 2014.
PubMed
2) Killu AM, Mazo A, Grupper A, et al:Super-response to cardiac resynchronization therapy reduces appropriate implantable cardioverter defibrillator therapy. Europace 20:1303-1311, 2018.
PubMed
3) Khairy P, Van Hare GF, Balaji S, et al:PACES/HRS Expert Consensus Statement on the Recognition and Management of Arrhythmias in Adult Congenital Heart Disease: developed in partnership between the Pediatric and Congenital Electrophysiology Society(PACES) and the Heart Rhythm Society(HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology(ACC), the American Heart Association(AHA), the European Heart Rhythm Association(EHRA), the Canadian Heart Rhythm Society(CHRS), and the International Society for Adult Congenital Heart Disease (ISACHD). Heart Rhythm 11:e102-165, 2014.
 
4) Hofferberth SC, Alexander ME, Mah DY, et al:Impact of pacing on systemic ventricular function in L-transposition of the great arteries. J Thorac Cardiovasc Surg 151:131-138, 2016.
 
P.167 掲載の参考文献
1) Halabi SA, Qintar M, Hussein A, et al:Catheter Ablation for Atrial Fibrillation in Heart Failure Patients:A Meta-Analysis of Randomized Controlled Trials. JACC Clin Electrophysiol 1:200-209, 2015.
 
2) Biase LD, Mohanty P, Mohanty S, et al:Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device:Results From the AATAC Multicenter Randomized Trial. Circulation 133:1637-1644, 2016.
 
3) 日本循環器学会/日本不整脈心電学会合同ガイドライン:不整脈非薬物治療ガイドライン(2018年改訂版). 2021更新. https://www.j-circ.or.jp/cms/wp-contaent/uploads/2018/07/JCS2018_kurita_nogami.pdf
 
4) 日本循環器学会/日本不整脈心電学会合同ガイドライン:2020年改訂版 不整脈薬物治療ガイドライン. 2021更新. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/01/JCS2020_Ono.pdf
 
5) 日本循環器学会/日本不整脈心電学会合同ガイドライン:2021年JCS/JHRSガイドラインフォーカスアップデート版 不整脈非薬物治療. 2021更新. https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Kurita_Nogami.pdf
 
6) Rehman KA, Wazni OM, Barakat AF, et al:Life-Threatening Complications of Atrial Fibrillation Ablation:16-Year Experience in a Large Prospective Tertiary Care Cohort. JACC Clin Electrophysiol 5:284-291, 2019.
 
7) Li WJ, Chen XQ, Xu LL, et al:SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials. Cardiovasc Diabetol 19:130, 2020.
 
8) Sutanto H, Dobrev D, Heijman J:Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac Arrhythmias. Int J Mol Sci 22:8994, 2021.
PubMed
P.183 掲載の参考文献
1) Ross J Jr, Braunwald E:Aortic stenosis. Circulation 38 (1 Suppl):61-67, 1968.
 
2) Otto CM, Burwash IG, Legget ME, et al:Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome. Circulation 95:2262-2270, 1997.
PubMed
3) 日本循環器学会/日本胸部外科学会/日本血管外科学会/日本心臓血管外科学会合同ガイドライン:2020年改訂版弁膜症治療のガイドライン. 2020. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/04/JCS2020_Izumi_Eishi.pdf
 
P.199 掲載の参考文献
1) 日本循環器学会/日本心臓病学会/日本心臓血管外科学会/日本血管外科学会/日本胸部外科学会合同ガイドライン:2021年改訂版 先天性心疾患, 心臓大血管の構造的疾患(structural heart disease)に対するカテーテル治療のガイドライン. 2021. https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Sakamoto_Kawamura.pdf
 
2) Boekstegers P, Hausleiter J, Baldus S, et al:Percutaneous interventional mitral regurgitation treatment using the Mitra-Clip system. Clin Res Cardiol 103:85-96, 2014.
PubMed
3) Geriatric Medicine Research. Dalhousie University. Clinical Frailty Scale:CFS Version 1. 2_EN. https://www.dal.ca/sites/gmr/our-tools/clinical-frailty-scale.html
 
4) 日本循環器学会/日本胸部外科学会/日本血管外科学会/日本心臓血管外科学会合同ガイドライン:2020年改訂版弁膜症治療のガイドライン. 2020. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/04/JCS2020_Izumi_Eishi.pdf
 
5) Mauri L, Foster E, Glower DD, et al:EVEREST II Investigators. 4-year results of a randomized controlled trial of percutaneous repair versus surgery for mitral regurgitation. J Am Coll Cardiol 62:317-328, 2013.
PubMed
6) Stone GW, Lindenfeld J, Abraham WT, et al:COAPT Investigators. Transcatheter Mitral-Valve Repair in Patients with Heart Failure. N Engl J Med 379:2307-2318, 2018.
PubMed
7) Obadia JF, Messika-Zeitoun D, Leurent G, et al:MITRA-FR Investigators. Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation. N Engl J Med 379:2297-2306, 2018.
 
8) 日本循環器学会/日本心不全学会合同ガイドライン:2021年度改訂版 循環器疾患における緩和ケアについての提言. 2021. https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Anzai.pdf
 
P.216 掲載の参考文献
1) 日本循環器学会/日本心不全学会合同ガイドライン:2021年JCS/JHFSガイドラインフォーカスアップデート版急性・慢性心不全診療. 2021. p.20. https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Tsutsui.pdf
 
2) 日本循環器学会/日本心臓血管外科学会/日本胸部外科学会/日本血管外科学会合同ガイドライン:重症心不全に対する植込型補助人工心臓ガイドライン(2021年度版). 2021. p.15-19. https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Ono_Yamaguchi.pdf
 
3) 日本胸部外科学会, J-MACS委員会:J-MACS Statistical Report. 2021. https://www.jpats.org/lib/files/society/jmacs/statistical_report_201006-202012.pdf
 
4) 補助人工心臓治療関連学会協議会:植込型補助人工心臓DT実施基準(2022.4.18改訂). 植込型補助人工心臟DT実施基準(j-vad.jp). 2021.
 
5) 戸田宏一:植込型補助人工心臓感染症. 人工臓器 47(3):227-229, 2018.
 
6) Carlo RB, David MZ, Samson HS, et al:Clinical and In Vitro Evidence That Left Ventricular Assist Device-Induced von Willebrand Factor Degradation Alters Angiogenesis. Circ Heart Fail 11(9):e004638, 2018.
 
P.233 掲載の参考文献
1) 日本循環器学会ほか:2016年版 心臓移植に関する提言. 2016. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2016_isobe_h.pdf
 
2) Fukushima N, Ono M, Saiki Y, et al:Registry Report on Heart Transplantation in Japan (June 2016). Circ J 81:298-303, 2017.
PubMed
3) Khush KK, Cherikh WS, Chambers DC, et al:International Society for Heart and Lung Transplantation. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation:Thirty-sixth adult heart transplantation report-2019 ; focus theme:Donor and recipient size match. J Heart Lung Transplant 38:1056-1066, 2019.
PubMed
4) 日本心臓移植研究会:心臓移植レジストリ報告 日本心臓移植研究会まとめ1999年2月～2020年12月31日. http://www.jsht.jp/2021/04/17/registry/japan/20201231レジストリ2.pdf
 

書評

最近チェックした商品履歴

Loading...